Background In cross-sectional studies there appears to be a link between calcium metabolism and blood pressure, and most studies have found a positive association between serum parathyroid hormone (PTH) and hypertension.
Introduction
Both epidemiological and experimental data link calcium metabolism to the regulation of blood pressure. A low calcium intake is thus associated with an increase in blood pressure [1, 2] , whereas calcium supplementation appears to have a blood pressure-lowering effect [3] . Similarly, supplementation with vitamin D, both to elderly women [4] as well as middle-aged men [5] , has been reported to reduce blood pressure significantly.
A drop in the level of serum ionized calcium elicits a compensatory increase in the secretion of parathyroid hormone (PTH). PTH in turn increases the serum ionized calcium level by mobilizing calcium from the skeleton, increasing intestinal calcium absorption, and decreasing renal calcium excretion [6] . In an individual without primary hyperparathyroidism, a high serum PTH level can therefore be considered a marker of the body being in a calcium deficit. In accordance with this, there is a positive association between serum PTH and blood pressure [7] [8] [9] [10] . Whether this association is a causal, or merely a parallel phenomenon is not known. In acute infusion studies it appears that PTH has a vasodilatory effect [11] , whereas the chronic infusion of PTH for 12 days has been reported to cause hypertension [12] .
If PTH is of importance for the development of hypertension, one would expect individuals with elevated serum PTH not only to have higher blood pressure, but also to increase their blood pressure more over time than those with normal PTH levels. In particular, one would expect those who increased their PTH levels to have the highest increase in blood pressure at a later examination. However, to our knowledge there are no longitudinal studies on PTH and blood pressure.
The Tromsø studies are population-based studies focusing on cardiovascular diseases and risk factors [13] . In 1994-1995 the fourth and in 2001 the fifth Tromsø studies were performed. Serum PTH was measured in samples from both studies, and as almost half of those participating in the fifth Tromsø study had also participated in the fourth, we had the opportunity to evaluate the prognostic value of serum PTH in relation to changes in blood pressure over time.
Methods
In the fourth Tromsø study 1994-1995 (for simplicity 1994 in the following) all men and women aged over 24 years who were living in the municipality of Tromsø, which is the major city in northern Norway, were invited to participate. A subgroup was invited to a second phase that included blood samples for hormone analysis. In the fifth Tromsø study in 2001 all men and women older than 29 years, living in the same area, and who participated in the second phase of the fourth Tromsø study or became 30, 40, 45, 60 or 75 years old during 2001, were invited to participate.
On both occasions a questionnaire including the use of blood pressure medication and smoking status was filled out. Height, weight, and blood pressure were measured as previously described [10] . Body mass index (BMI) was calculated as weight divided by squared height. Blood samples were drawn in the non-fasting state. In the fourth Tromsø study serum calcium was analysed within a week after sampling, whereas serum PTH was analysed in 2001. Samples from the fifth Tromsø study were analysed within 2 months for serum calcium and creatinine, and for serum PTH within 12 months. All samples were stored frozen at À708C. The analytical methods were as reported before [14] . Of importance in the present connection is that the same method for the PTH analysis was used on both occasions, with the same reference levels. In our laboratory the reference range for serum calcium is 2.20-2.60 mmol/l, for serum PTH 1.1-6.8 pmol/l for those under 51 years and 1.1-7.5 pmol/l for those over 50 years, and serum creatinine 55-100 mmol/l for women and 70-120 mmol/l for men. Individuals using blood pressure medication during the study period 1994-2001 and those with serum calcium greater than 2.60 mmol/l in 1994 were excluded.
Statistics
Normal distribution was evaluated with the visual inspection of histograms and the determination of skewness and kurtosis, and all variables used as dependent variables were considered normally distributed. To test for main effects and interactions between serum PTH quartiles, smoking status and sex, a factor analysis was performed using a general linear model with delta systolic blood pressure (systolic blood pressure from 2001 minus systolic blood pressure from 1994) as a dependent variable, serum PTH quartile, smoking status and sex as factors, and systolic blood pressure, age, BMI, and serum calcium from 1994 as independent variables. In this model there were no significant interactions between the factors tested regarding delta systolic blood pressure, but there was a significant effect of sex, and in the following all data are analysed sex specifically. As there was no significant effect of serum calcium, this variable was excluded from the linear regression models. Unless otherwise stated, all data are expressed as mean AE SD. All tests were performed two-sided, and P < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 12.0 (SPSS Inc., Chicago, Illinois, USA).
Results

Subjects
A total of 27 180 subjects participated in the fourth Tromsø study, and of these 3570 had serum PTH measured. A total of 8128 subjects attended the fifth Tromsø study, and of these 7954 had PTH measured. A total of 2608 had serum PTH, serum calcium, blood pressure, height, and weight measured, and gave information on smoking status and the use of blood pressure medication on both occasions. Of these subjects 38 had serum calcium greater than 2.60 mmol/l and were therefore excluded together with 408 subjects who were, or had been, using blood pressure medication in 1994. Of the remaining 2162, 378 were using or had used blood pressure medication during the observation period up to 2001, leaving 1784 subjects for the present analysis on serum PTH and blood pressure changes. The characteristics of this cohort are shown in Table 1 . Between 1994 and 2001 there was a significant increase in BMI, systolic and diastolic blood pressure, and serum PTH. There was a significant decrease in serum calcium and in the number of smokers. There was a highly significant correlation between serum PTH from 1994 and 2001 (r ¼ 0.59 for men and r ¼ 0.63 for women, P < 0.001).
Relationship between serum parathyroid hormone 1994 and delta blood pressure In the linear regression model serum PTH was a significant and positive predictor of delta systolic blood pressure in men, but not in women. There was no significant effect on delta diastolic blood pressure (Table 2 ). When serum PTH was grouped in quartiles, there was with increasing quartiles a significant increase in age in both sexes, a significant increase in BMI in women, a significant increase in systolic blood pressure in both sexes, and a significant increase in diastolic blood pressure in men. For men, there was a significant and gradual increase in delta systolic blood pressure along the serum PTH quartiles, with a difference of 3.5 mmHg between the highest and the lowest quartiles. When looking specifically at those with the highest PTH levels (greater than the 97.5 percentile), all the above differences were even more pronounced (Table 3) .
Relationship between delta serum parathyroid hormone and delta blood pressure For the calculation of delta PTH z-scores were used. Similar to serum PTH, delta serum PTH was in the linear regression model a significant predictor of delta systolic blood pressure in men, but not in women. There was no significant relationship between delta serum PTH and delta diastolic blood pressure (Table 2 ). When delta serum PTH was grouped in quartiles, there was in both sexes with increasing quartile a significant decrease in serum PTH from 1994, whereas age, BMI, systolic and diastolic blood pressure from 1994 were similar along the quartiles. There was in the men a non-significant (P ¼ 0.15) increase in delta systolic blood pressure of 2.0 mmHg along the quartiles (Table 4) .
Discussion
In the present study we have found that serum PTH in men is a positive predictor of an increase in systolic blood pressure (delta systolic blood pressure) measured 6-7 years later. To our knowledge, this has not been reported before, and is yet another indication that PTH may be involved in the development of hypertension.
As expected [7] [8] [9] [10] , there was a significant correlation between systolic blood pressure and serum PTH measured in 1994. However, the association between Parathyroid hormone and blood pressure Jorde et al. 1641 Values of jtj > 1.96, jtj > 2.58, and jtj > 3.29 correspond to P < 0.05, P < 0.01, and P < 0.001, respectively. serum PTH and delta systolic blood pressure was not the result of covariation between serum PTH and blood pressure, as there was a negative association between systolic blood pressure in 1994 and delta systolic blood pressure, probably reflecting a 'regression towards the mean' between the two measurements. In addition, the inclusion or exclusion of systolic blood pressure from 1994 in the linear regression model had no effect on the relationship between serum PTH and delta systolic blood pressure.
The difference in delta systolic blood pressure between the highest and the lowest serum PTH quartiles was 3.5 mmHg, which is comparable with the difference in delta blood pressure between older and younger men. Men older than 64 years in 1994 had a mean increase in systolic blood pressure of 6.5 mmHg, whereas those less than 50 years had a mean increase of 3.1 mmHg during the follow-up period. Furthermore, in the linear regression model, serum PTH and age had almost identical standardized regression coefficients towards delta systolic blood pressure.
The mean serum PTH level in 2001 was approximately 20% or approximately 0.7 pmol/l higher than that from 1994. This can partly be ascribed to the subjects being 7 years older in 2001 as the difference in serum PTH between those in their fifties compared with those in their sixties are approximately 0.3 pmol/l [10] . In addition, there was probably a slight degradation of PTH in the samples during storage. When evaluating an increase in serum PTH (delta serum PTH) as a predictor of change in blood pressure, we therefore transformed the serum PTH values to z-scores. However, this transformation had only marginal effects on the results, and did not affect any of the differences that were statistically significant. Used as a continuous variable in this way, delta serum PTH was a significant predictor of an increase in systolic blood pressure, but did not reach statistical significance when analysed for linear trend along quartiles. Similar to the relationship between systolic blood pressure from 1994 and delta systolic blood pressure, there was a negative relationship between serum PTH from 1994 and delta serum PTH. In spite of this, both serum PTH and delta serum PTH were positively associated with delta systolic blood pressure. This strengthens the assumption of a true relationship between PTH and blood pressure, and makes it unlikely that our observation was only a statistical phenomenon.
There was a highly significant correlation between serum PTH from 1994 and 2001. Accordingly, those with high serum PTH levels in 1994 also tended to have high levels in 2001. As a high level of serum PTH in 1994 predicted an augmented increase in blood pressure 7 years later, it must indicate that, if PTH is of causal importance for the development of hypertension, its effect does not level off with time. In this respect it is noteworthy that the opposite relationship was seen between BMI and delta systolic blood pressure. A high BMI in 1994 was thus not positively related to delta blood pressure, whereas delta BMI was highly, and much more than delta PTH, associated with an increase in blood pressure during the observation period.
A positive association between serum PTH and an increase in later blood pressure is of course no proof of causality. A high serum PTH is only a marker of calcium deficit, and other variables such as intakes of calcium or vitamin D, as well as levels of serum ionized calcium and serum 25-hydroxyvitamin D may be the causative factor(s) regarding blood pressure, and not PTH. Furthermore, the intake of calcium as well as vitamin D is in parallel with other nutrients, and it is well known that the high degree of intercorrelation among dietary factors makes it difficult to identify the importance of single factors [15] . In addition, there are other factors released from the parathyroid glands, such as parathyroid hypertensive factor [16] and endothelin [17] , which are related to calcium metabolism [18] and blood pressure [16, 19] . The relationship between PTH and blood pressure found by us could thus simply reflect covariation with other more potent hypertensive factors. In hypertensive subjects with a high salt intake there is an increased urinary excretion of sodium and calcium, and this renal leak of calcium would lead to a compensatory increase in PTH. It is therefore possible that high blood pressure could cause, and not be the result of, an elevated serum PTH level [20] .
On the other hand, there are several mechanisms by which PTH might affect the blood pressure. PTH thus activates renal 1-alpha-hydroxylase resulting in increased 1.25-dihydroxyvitamin D levels, which again increase the calcium influx into vascular smooth muscle cells, causing an increase in vascular tone and blood pressure [21] . Furthermore, PTH has been reported to have a prosclerotic effect on vascular smooth muscle cells [22] , which may contribute to vessel wall thickening and arteriosclerosis.
Our study has several shortcomings. First, we only had serum creatinine levels from the fifth Tromsø study, and there was a significant correlation between serum PTH and serum creatinine (r ¼ 0.29, P < 0.001, men). Accordingly, our results could be the result of covariation between serum PTH and serum creatinine. However, this relationship was caused by the higher creatinine levels only. Therefore, if looking at the male cohort with serum creatinine below the 75 percentile (serum creatinine < 102 mmol/l) the association between serum PTH and serum creatinine disappeared (r ¼ 0.03, P ¼ 0.09), whereas the relationship between serum PTH and delta serum PTH on delta systolic blood pressure was still statistically significant. Second, we have no explanation for why the effect of PTH on delta systolic blood pressure was not seen in women, even though they had a similar cross-sectional relationship between serum PTH and blood pressure as the men. Third, the serum samples from 1994 had been stored for many years before analysis and there appeared to have been some degradation of PTH during storage. We cannot guarantee that the degradation was similar in all samples, but the strong correlation between serum PTH values from 1994 and 2001 do indicate that this was the case. Furthermore, an uneven degradation would most likely mask and not cause a relationship between serum PTH and blood pressure. If the percentage decline in the serum PTH level caused by storage was the same throughout the PTH range, the use of absolute values to calculate delta PTH could introduce an error. Therefore, if the absolute increase in serum PTH was similar, those with a high value in 1994 would, because of a higher decline during storage, get a higher delta value than those with a lower level in 1994. Therefore, we transformed the serum PTH values to z-scores to correct for storage degradation, and accordingly, the delta PTH values given reflect a change in PTH rank, and not a change in absolute value. Finally, it must be admitted that the effect of delta serum PTH on the blood pressure increase was, although statistically significant, marginal and needs confirmation in even larger studies.
In conclusion, we have found that serum PTH is a positive predictor of an increase in systolic blood pressure in men. However, whether there is a causal relationship between PTH and hypertension needs to be established in future studies.
